About Berry Oncology

Berry Oncology utilizes cfDNA multi-dimensional whole genome sequencing technology to enhance early cancer detection and tumor diagnosis. Their products, including the multi-cancer early screening tool and liver cancer screening solution, provide precise molecular diagnostics for high-risk populations, improving patient outcomes through timely intervention.

```xml <problem> Current methods for early cancer detection and tumor diagnosis often lack the sensitivity and specificity needed to identify tumors at an early stage, particularly for high-risk populations. Traditional screening methods may also be invasive or have limited accessibility, hindering widespread adoption and timely intervention. </problem> <solution> Berry Oncology leverages cell-free DNA (cfDNA) multi-dimensional whole-genome sequencing (WGS) technology to provide advanced molecular diagnostics for early cancer detection and tumor diagnosis. Their core technology, HIFI, enables the development of screening products like the multi-cancer early screening tool (全思宁TM) and the liver cancer screening solution (莱思宁®). These solutions aim to improve patient outcomes by enabling earlier and more precise detection of tumors, leading to timely intervention and treatment. </solution> <features> - cfDNA multi-dimensional whole-genome sequencing (WGS) technology for comprehensive genomic analysis. - HIFI technology platform for enhanced sensitivity and specificity in cancer detection. - Multi-cancer early screening tool (全思宁TM) for early detection of multiple cancer types. - Liver cancer screening solution (莱思宁®) for early detection of liver cancer, validated in prospective cohort studies. - Products designed for high-risk populations to facilitate targeted screening efforts. </features> <target_audience> The primary target audience includes individuals at high risk for cancer, healthcare providers, and hospitals seeking advanced molecular diagnostic tools for early cancer detection and diagnosis. </target_audience> ```

What does Berry Oncology do?

Where is Berry Oncology located?

Berry Oncology is based in Ho, China.

When was Berry Oncology founded?

Berry Oncology was founded in 2017.

Location

Ho, China

Founded

2017

Find Investable Startups and Competitors

Search thousands of startups using natural language

AI voice (2021+)underground pipe robots energy flexibility software

Start Searching

Berry Oncology

⚠️ AI-generated overview based on web search data – may contain errors, please verify information yourself! You can claim this account with your email domain to make edits.

Executive Summary

berryoncology.com

Founded 2017 – Ho, China

Funding

No funding information available.

Team

No team information available.

Company Description

Problem

Current methods for early cancer detection and tumor diagnosis often lack the sensitivity and specificity needed to identify tumors at an early stage, particularly for high-risk populations. Traditional screening methods may also be invasive or have limited accessibility, hindering widespread adoption and timely intervention.

Solution

Berry Oncology leverages cell-free DNA (cfDNA) multi-dimensional whole-genome sequencing (WGS) technology to provide advanced molecular diagnostics for early cancer detection and tumor diagnosis. Their core technology, HIFI, enables the development of screening products like the multi-cancer early screening tool (全思宁TM) and the liver cancer screening solution (莱思宁®). These solutions aim to improve patient outcomes by enabling earlier and more precise detection of tumors, leading to timely intervention and treatment.

Features

cfDNA multi-dimensional whole-genome sequencing (WGS) technology for comprehensive genomic analysis.

HIFI technology platform for enhanced sensitivity and specificity in cancer detection.

Multi-cancer early screening tool (全思宁TM) for early detection of multiple cancer types.

Liver cancer screening solution (莱思宁®) for early detection of liver cancer, validated in prospective cohort studies.

Products designed for high-risk populations to facilitate targeted screening efforts.

Target Audience

The primary target audience includes individuals at high risk for cancer, healthcare providers, and hospitals seeking advanced molecular diagnostic tools for early cancer detection and diagnosis.